Physiogenex will be presenting a study dealing with the effects of obeticholic acid and elafibranor in various animal models of NASH/hepatic fibrosis.
The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Friday, September the 14th, from 11:45am to 1:15pm, poster #10.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.


efficitur. Praesent facilisis Lorem dolor quis elit. non vel, libero. risus.